An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
NCT ID: NCT01454531
Last Updated: 2015-03-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
199 participants
INTERVENTIONAL
2011-06-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy
NCT02069535
An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy
NCT01568190
An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy
NCT01674595
A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea
NCT02849210
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
NCT07348302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AVANZ Phleum pratense
AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
AVANZ Phleum pratense
AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AVANZ Phleum pratense
AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive SPT to Phleum pratense
* Positive specific IgE against Phleum pratense
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALK-Abelló A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JOAQUIN SASTRE, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
FUNDACIÓN JIMÉNEZ DIAZ
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Basurto
Bilbao, Bilbao, Spain
Fundación Jiménez Diaz
Madrid, Madrid, Spain
Hospital Infanta Elena
Madrid, Madrid, Spain
Hospital Universitari Politecnic La Fe
Valencia, Valencia, Spain
Hospital Nuestra Señora de Sonsoles
Ávila, , Spain
Hospital Universitario Infanta Cristina
Badajoz, , Spain
Complejo Hospitalario de Burgos
Burgos, , Spain
Hospital Nuestra Señora de La Montaña
Cáceres, , Spain
H. Campo Arañuelo
Cáceres, , Spain
Hospital Universitario de La Princesa
Madrid, , Spain
Hospital Gregorio Marañón
Madrid, , Spain
Hospital Infanta Leonor
Madrid, , Spain
Hospital Univesitario Fundación Hospital de Alcorcón
Madrid, , Spain
Hospital Carlos Haya
Málaga, , Spain
Hospital Rio Carrion
Palencia, , Spain
Hospital Santa Bárbara
Puertollano, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Univeritario Marques de Valdeilla
Santander, , Spain
Hospital Santiago Apostol
Vitoria-Gasteiz, , Spain
Hospital Virgen de La Concha
Zamora, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AV-G-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.